Vertex Among Four Hopefuls Seeking EMA's Elusive Speedy Review
Vertex’s triple combination regimen for cystic fibrosis and two Ebola vaccines from Janssen are among the latest potential new products being considered for accelerated assessment by the European Medicines Agency.
You may also be interested in...
The outcomes of six requests for accelerated assessment that companies have made for their planned marketing authorization applications in the EU are still unknown.
People at risk of contracting the Ebola virus in the latest outbreak in the Democractic Republic of Congo are to have another vaccination option in the form of Janssen’s experimental prime-boost vaccine regimen, Ad26.ZEBOV/MVA-BN.
It's decision time again at the European Medicines Agency and Roche's Polivy and AstraZeneca's Qternmet are among the products up for an opinion on whether they should be approved in the EU.